ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 on Phase 3 CAIRO5 Study: FOLFOXIRI + Bev vs. FOLFOX/FOLFIRI + Bev in Initially Unresectable Colorectal Liver Metastases and Right-Sided and/or RAS/BRAFV600Em Primary Tumor

20 views
June 29, 2022
Comments 0
Login to view comments. Click here to Login